Collegium Pharmaceutical to Present at 11th Annual BIO Investor Forum

<0> Collegium Pharmaceutical, Inc.Michael Heffernan, 401-762-2000, x220President </0>

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain is pleased to announce that Michael Heffernan, President and CEO of Collegium, will present a corporate overview at the 11 Annual BIO Investor Forum in San Francisco, CA. The Collegium presentation will take place on Tuesday, October 9, 2012 at 8:30AM PDT in the Pacific Heights Room in the Palace Hotel in San Francisco.

The BIO Investor Forum is an annual, high-profile, international biotech investor conference focused on connecting early and established private companies, as well as emerging public companies, with leading investors.

The DETERx drug delivery platform consists of a multi-particulate matrix formulation in a capsule. While developed primarily to provide tamper-resistant properties to protect against common methods of tampering such as chewing, crushing, insufflation and extraction for IV injection, the multi-particulate design is expected to enable patients with difficulty swallowing to open the capsule and administer the contents on food or via a gastronomy tube, while maintaining the extended-release properties of the product. DETERx technology can be used with drugs that are commonly abused such as opioids and amphetamines, as well as drugs that have narrow therapeutic windows that would benefit from protection against misuse such as breaking, crushing, grinding or dissolving the product. The formulation platform is covered by U.S. and international patents and patent applications. Oxycodone DETERx (COL-003) is the first of a number of product candidates using the DETERx platform.

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx formulation platform for the treatment of chronic pain. The DETERx oral drug delivery technology provides extended-release delivery, unique tamper-resistant properties, and flexible dose administration options. For more information, visit the Company’s website at .

Suggested Articles

The series A sets ex-Gilead R&D chief Norbert Bischofberger up to advance efforts to hit historically undruggable targets. 

Gilead Chief Scientific Officer and R&D chief John McHutchison, M.D., is leaving one year after he replaced R&D lead Norbert Bischofberger, Ph.D.

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.